(NYSE: TEVA) TEVA PHARMACEUTICAL INDUSTRIES's forecast annual revenue growth rate of 1.39% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.17%.
TEVA PHARMACEUTICAL INDUSTRIES's revenue in 2022 is $15,558,000,000.On average, 5 Wall Street analysts forecast TEVA's revenue for 2022 to be $17,439,165,878,120, with the lowest TEVA revenue forecast at $17,257,285,714,081, and the highest TEVA revenue forecast at $17,766,082,492,959. On average, 5 Wall Street analysts forecast TEVA's revenue for 2023 to be $17,753,462,227,614, with the lowest TEVA revenue forecast at $17,189,365,457,957, and the highest TEVA revenue forecast at $18,190,903,320,051.
In 2024, TEVA is forecast to generate $18,004,188,681,676 in revenue, with the lowest revenue forecast at $17,134,958,190,504 and the highest revenue forecast at $18,576,195,601,810.